Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other Accumulated Expenses (2021 - 2024)

Lyra Therapeutics (LYRA) has disclosed Other Accumulated Expenses for 4 consecutive years, with $475000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Other Accumulated Expenses fell 61.41% to $475000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $475000.0, a 61.41% decrease, with the full-year FY2024 number at $475000.0, down 61.41% from a year prior.
  • Other Accumulated Expenses was $475000.0 for Q4 2024 at Lyra Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.2 million in Q4 2023 to a low of $40000.0 in Q1 2022.
  • A 4-year average of $371100.0 and a median of $214500.0 in 2021 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 130.0% in 2022, then plummeted 61.41% in 2024.
  • Lyra Therapeutics' Other Accumulated Expenses stood at $633000.0 in 2021, then grew by 4.11% to $659000.0 in 2022, then surged by 86.8% to $1.2 million in 2023, then tumbled by 61.41% to $475000.0 in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Other Accumulated Expenses are $475000.0 (Q4 2024), $1.2 million (Q4 2023), and $659000.0 (Q4 2022).